Release date: 2017-05-23
Speaking of Organo's 3D printing liver and kidney tissue, I am sure that everyone is no stranger. This year, the bioprinting company has released several embarrassing data from the company's exVive 3D printing organization. This week, Organovo showed new data showing that 3D printed tissue can survive and function in experimental animals.
Previously, Organovo implanted several of their 3D printed liver tissue into the liver of healthy NOD/SCID mice. The new data reflects an early study of the treatment of alpha-antitrypsin deficiency, a genetic disorder that causes lung or liver disease.
The body creates a protein to protect the lungs and liver from damage, but when the protein is not produced enough, the symptoms appear, making patients prone to emphysema and cirrhosis.
Organovo's 3D printed liver tissue consists of human hepatocytes and selected non-parenchymal cells that are implanted in experimental animals with the above defects. After 60 days, the 3D printing organization shows the functionality of moving in, staying, and continuing. Compared to an earlier experiment, the 3D printing organization only showed 28 days of functionality, which is a significant improvement. Pathological evaluation showed that animals implanted with 3D printed tissue had better liver health than controls that were not implanted with 3D printed liver tissue.
“In the United States, tens of thousands of people suffer from congenital metabolic defects (IEM), and the average annual cost per patient is more than $250,000, and this is only the cost of medication. Organovo is advancing new Direct surgical implant treatment. The positive results demonstrated by all the research data support our continued preclinical development of the Organovo 3D bioprinting organization," Organovo said.
Organovo plans to submit a new drug application to the US Food and Drug Administration for its 3D bioprinted liver tissue by 2020. Over the next year and a half, the company plans to optimize the final design of its 3D printed liver tissue and continue with pre-GLP studies, including efficacy, safety, and dose studies in small experimental animals with IEM. In addition, Organovo plans to focus first on pediatric IEMs and is planning to seek orphan design in the United States, as well as working with contract research organizations to identify research that will make it possible to investigate new drug applications.
Source: Tiangongshe
Dietary supplements take vitamins, minerals and extracts with relatively clear structure-activity relationship as the main raw materials, and supplement the necessary nutrients and biologically active substances for the human body through oral intake to achieve the purpose of improving the body's health and reducing the risk of disease. Available in concentrated forms such as doses or capsules. Foods in traditional form with added nutrients or biologically active substances.
Dietary supplement,New Dietary Ingredient,Dietary Supplement Product,Food Supplements
YT(Xi'an) Biochem Co., Ltd. , https://www.ytnutra.com